>

Antibody-Drug Conjugate Shows Efficacy in Epithelial Cancers

Sacituzumab Govitecan SG Demonstrates Promising Results in Clinical Trials

Targeted Therapy for Brain Metastases and Recurrent Glioblastoma

WEB Sacituzumab Govitecan SG, an antibody-drug conjugate that targets the TROP-2 protein, has shown promising efficacy in patients with epithelial cancers. The drug has been tested in clinical trials for treating brain metastases from breast cancer and recurrent glioblastoma. WEB Sacituzumab Govitecan SG has demonstrated a favorable tolerability profile with promising clinical outcomes, offering hope for patients with these aggressive forms of cancer.